Alemtuzumab induction in renal transplantation.

  title={Alemtuzumab induction in renal transplantation.},
  author={Michael J. Hanaway and E. Steve Woodle and Shamkant P. Mulgaonkar and V. Ram Peddi and Dixon B Kaufman and M. Roy First and Richard Croy and John Holman},
  journal={The New England journal of medicine},
  volume={364 20},
BACKGROUND There are few comparisons of antibody induction therapy allowing early glucocorticoid withdrawal in renal-transplant recipients. The purpose of the present study was to compare induction therapy involving alemtuzumab with the most commonly used induction regimens in patient populations at either high immunologic risk or low immunologic risk. METHODS In this prospective study, we randomly assigned patients to receive alemtuzumab or conventional induction therapy (basiliximab or… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 118 extracted citations


Publications referenced by this paper.
Showing 1-10 of 23 references

Antibody-mediated rejection (AMR) in renal allograft recipients treated with alemtuzumab induction

  • J Pascual, J Pirsch, J Torrealba
  • Am J Transplant 2008;8:Suppl 2:237. abstract…
  • 2012

A prospective , randomized , double - blind , placebo - controlled multicenter trial comparing early ( 7 day ) corticosteroid cessation versus long - term corticosteroid ther

  • RE Boardman, RR Alloway, JW Alexander
  • Ann Surg
  • 2008

Similar Papers

Loading similar papers…